《大行報告》野村降泰格醫藥(03347.HK)評級至「中性」 上調目標價至102.23元
野村發表評級報告,將泰格醫藥(03347.HK)去年收入預測下調1.4%,以反映第四季受疫情影響,惟將其盈利預測上調5.9%;至於今、明年的收入及盈利預測大致上維持不變,該行預料公司今年收入達85.8億元人民幣,按年增長17.9%的。意味著撇除新冠相關項目,年內銷售或按年升36.7%。其毛利率恢復至42.8%,盈利增長則按年升34%至26億元人民幣。該行將其目標價由80.36元上調至102.23元,由於股價已大幅反彈,將其評級由「買入」降至「中性」。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.